Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafoxiparin pilot study in pre-eclampsia during pregnancy
2020-004692-40Phase 2Terminated
- Sponsor
- Dilafor AB
- Start
- May 2021
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tafoxiparin in preeclampsia (2 arms), sponsored by Dilafor AB. Primary endpoint: Safety and tolerability. Started May 2021; status: terminated.
02
Drugs
tafoxiparin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2020-004692-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004692-40.